These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36459346)

  • 1. Bayesian Methods in Human Drug and Biological Products Development in CDER and CBER.
    Ionan AC; Clark J; Travis J; Amatya A; Scott J; Smith JP; Chattopadhyay S; Salerno MJ; Rothmann M
    Ther Innov Regul Sci; 2023 May; 57(3):436-444. PubMed ID: 36459346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delegations of authority and organization; Center for Biologics Evaluation and Research, Center for Devices and Radiological Health, and Center for Drug Evaluation and Research--FDA. Final rule.
    Fed Regist; 1991 Nov; 56(225):58758-9. PubMed ID: 10115699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The U.S. Food and Drug Administration's Complex Innovative Trial Design Pilot Meeting Program: Progress to date.
    Price D; Scott J
    Clin Trials; 2021 Dec; 18(6):706-710. PubMed ID: 34657476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective.
    Schwieterman WD
    Drug Discov Today; 2006 Oct; 11(19-20):945-51. PubMed ID: 16997146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the Regulatory Pathways Used to Develop, Evaluate, Authorize, and Approve New Drugs and Vaccines in the United States.
    Domachowske JB
    J Pediatric Infect Dis Soc; 2024 Jul; 13(Supplement_2):S93-S102. PubMed ID: 38995086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revision of the requirements for constituent materials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2011 Apr; 76(71):20513-8. PubMed ID: 21491807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The history of regulatory system for plasma fractionation products in the United States].
    Fukuzawa M; Tsutani K
    Yakushigaku Zasshi; 2014; 49(2):205-13. PubMed ID: 25799842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA regulations for growth factors and related products.
    Chapekar MS; Gunter KC
    EXS; 1992; 61():471-8. PubMed ID: 1617242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory concerns in the development of biologic-biomaterial combinations. United States Food and Drug Administration.
    Chapekar MS
    J Biomed Mater Res; 1996; 33(3):199-203. PubMed ID: 8864892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additively manufactured medical products - the FDA perspective.
    Di Prima M; Coburn J; Hwang D; Kelly J; Khairuzzaman A; Ricles L
    3D Print Med; 2016; 2():. PubMed ID: 29974058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2022 in review: FDA approvals of new medicines.
    Kinch MS; Kraft Z; Schwartz T
    Drug Discov Today; 2023 Aug; 28(8):103622. PubMed ID: 37201782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Food and Drug Administration: Helping pharmacists ensure that patients receive high-quality medicines.
    Kremzner M
    J Am Pharm Assoc (2003); 2016; 56(2):201-2. PubMed ID: 27000171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical research strategies in biotechnology.
    Vincent-Gattis M; Webb C; Foote M
    Biotechnol Annu Rev; 2000; 5():259-67. PubMed ID: 10875003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Retrospective Review of Center for Biologics Evaluation and Research Advisory Committee Meetings in the Context of the FDA's Benefit-Risk Framework.
    Mutanga JN; Nukala U; Rodriguez Messan M; Yogurtcu ON; McCormick Q; Sauna ZE; Whitaker BI; Forshee RA; Yang H
    AAPS J; 2023 Feb; 25(1):24. PubMed ID: 36759415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International Conference on Harmonisation; Electronic Transmission of Postmarket Individual Case Safety Reports for Drugs and Biologics, Excluding Vaccines; Availability of Food and Drug Administration Regional Implementation Specifications for ICH E2B(R3) Reporting to the Food and Drug Administration Adverse Event Reporting System. Notice of Availability.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Jun; 81(121):40890-1. PubMed ID: 27373012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016.
    Alexander GC; Ogasawara K; Wiegand D; Lin D; Breder CD
    Ther Innov Regul Sci; 2019 Nov; 53(6):752-758. PubMed ID: 30509142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How Has CDER Prepared for the Nano Revolution? A Review of Risk Assessment, Regulatory Research, and Guidance Activities.
    Tyner KM; Zheng N; Choi S; Xu X; Zou P; Jiang W; Guo C; Cruz CN
    AAPS J; 2017 Jul; 19(4):1071-1083. PubMed ID: 28421428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An FDA/CDER perspective on nonclinical testing strategies: Classical toxicology approaches and new approach methodologies (NAMs).
    Avila AM; Bebenek I; Bonzo JA; Bourcier T; Davis Bruno KL; Carlson DB; Dubinion J; Elayan I; Harrouk W; Lee SL; Mendrick DL; Merrill JC; Peretz J; Place E; Saulnier M; Wange RL; Yao J; Zhao D; Brown PC
    Regul Toxicol Pharmacol; 2020 Jul; 114():104662. PubMed ID: 32325112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. United States Food and Drug Administration Regulation of Human Cells, Tissues, and Gene Therapies.
    Sanduja S; Lessey-Morillon L; Allen R; Wang X; Imperato G; Arcidiacono J
    Adv Exp Med Biol; 2023; 1430():71-89. PubMed ID: 37526843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.